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Hemovigilance systems allow reporting of adverse occurrences 
associated with blood transfusion to a central database where 
events can be reviewed and analyzed for the benefit of patients and 
donors. Hemolytic and serologic transfusion reactions are among 
the many types of reactions reported to these systems. The Notify 
Library, a database of adverse events associated with medical 
products of human origin, has incorporated hemovigilance into 
its didactic resources. Students and practitioners are encouraged 
to use the electronic library and to further enhance this resource 
through review and recommendation of additional publications 
in the area of immunohematology. Immunohematology 
2017;33:159–164.
Key Words: biovigilance, hemovigilance, transfusion 
reactions, hemolytic transfusion reactions, serologic 
transfusion reactions
Advances in science and health care technology have 
led to the development of replacement medicine, with many 
human body components being collected for the preparation of 
medical products of human origin (MPHO). These collections 
encompass a wide range of medical products—from cells (e.g., 
human stem cells from peripheral blood, bone marrow, or cord 
blood; gametes) and tissues (e.g., corneas, musculoskeletal 
tissues) to blood and blood components and organs, from 
anatomical components to secretions (e.g., breast milk) and 
excretions—all originating from the human body. Donated by 
a human with the goal of benefitting others, these MPHO have 
indeed saved and improved human lives through their clinical 
application.
Vigilance is a powerful tool for improving safety and 
quality. Vigilance includes monitoring and reporting adverse 
events and outcomes associated with therapeutic treatments. 
Originating from hemovigilance for blood components, 
biovigilance is the term used for the monitoring of adverse 
outcomes associated with all MPHO. Sharing the lessons 
learned from adverse outcomes can allow for significant 
process improvements for the greater protection of donors 
and patients. These benefits apply not only to the institution 
where the incident occurred but also to other institutions 
where an identical or similar incident might occur. Detection, 
investigation, and communication of adverse events provide 
the transparency and openness that these uniquely sourced 
medical treatments demand.
The World Health Organization (WHO) promotes the 
governance of MPHO in a manner that acknowledges their 
exceptional nature. From donation to the follow-up care of 
the recipient, MPHO have a shared exposure to risks from 
breaches of ethical, legal, and safety standards—for example, 
the risk of disease transmission and consequent morbidity or 
mortality. Ensuring the protection of the donor, the recipient, 
and society as a whole requires establishment of globally 
consensual principles to govern the use of MPHO, such as the 
noncommercial nature of the human body and its parts and 
strict traceability associated with vigilance and surveillance. 
The Notify Library1 is the first WHO initiative that covers 
vigilance across the full MPHO scope.
Hemovigilance
Hemovigilance of blood transfusions encompasses a set 
of surveillance procedures that cover the entire collection 
to transfusion process: from the donor and donation, to the 
processing of the donor’s blood and its components, to their 
provision and transfusion to patients, to patient follow-
up. Hemovigilance includes the monitoring, reporting, 
investigation, and analysis of adverse events related to the 
donation, processing, and transfusion of blood, as well as 
the development and implementation of recommendations to 
prevent occurrence or recurrence.2
Hemovigilance systems arose as a response to the threat 
to the blood supply from emerging infections, such as HIV 
and the hepatitis viruses. Hemovigilance was first developed 
in Japan and then in France in 1993, featuring mandatory 
reporting. The UK developed the first voluntary system in 
1996, called Serious Hazards of Transfusion (SHOT).3 Over the 
years, systematic analyses from these systems and subsequent 
process improvements have led to enhanced patient safety.3–5 
In 2002, the European Union (EU) Commission Directive 
2002/98/EC set standards of quality and safety for the 
collection, testing, processing, storage, and distribution of 
human blood and blood components and amended Directive 
2001/83/EC, thereby mandating hemovigilance in the 
EU. Subsequently, other countries around the world have 
established hemovigilance systems, adopting either active or 
passive hemovigilance reporting. Systems engaging in active 
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hemovigilance require a confirmation of a transfusion reaction 
or the lack thereof after every transfusion. In 1998, the 
European Haemovigilance Network was established; in 2009, 
it evolved into the International Haemovigilance Network to 
share common definitions, findings, and interventions and to 
promote transfusion safety worldwide.
The Haemovigilance Working Party of the International 
Society of Blood Transfusion (ISBT) has developed transfusion 
reaction definitions (Tables 1 and 2) and imputability criteria 
(Table 3). Imputability is the strength of the relationship 
between the transfusion and the adverse transfusion reaction 
and is usually determined through a thorough investigation 
of the adverse reaction. Standard definitions for hemolytic 
transfusion reactions include acute hemolytic transfusion 
reactions (AHTRs), delayed hemolytic transfusion reactions 
(DHTRs), and delayed serologic transfusion reactions (DSTRs) 
(Table 1).2 Non-hemolytic transfusion reactions are described 
in Table 2.
Notify Library
The Notify Library is a database developed through a 
collaboration of WHO and the Italian National Transplant 
Center (CNT).6 It supports the sharing of published vigilance 
information for teaching purposes and for greater public 
transparency on the use of MPHO. The library aims to support 
three key audiences: the general public (especially potential 
donors or recipients), health professionals working in donor 
detection and selection or in the clinical application of MPHO, 
and health authorities responsible for vigilance systems. It 
aims to be comprehensive, describing all types of reactions 
or events that might have teaching value and assist in the 
estimation of risk.
The core of the Notify Library Web site (www.notifylibrary.
org) includes an online publicly accessible relational database 
of adverse occurrences collected and analyzed by dedicated 
editorial groups of international experts, regulators, and 
clinicians. The database is not a vigilance reporting program 
but rather a collection of information identified primarily by 
review of published articles in scientific journals and/or books. 
It also includes case reports from regulatory or professional 
vigilance programs (gray literature). Sources include events 
that may have occurred in procurement and processing, as 
well as in the clinical application, of blood, organs, tissues, 
and cells used in transfusion, transplantation, and assisted 
reproduction. For each adverse occurrence type, at least one 
reference is cited. The project’s collaborating international 
experts provide a structured analysis, focused in particular on 
how the adverse occurrence was recognized and how it was 
shown to have been associated with the donation, processing, 
or clinical application of MPHO. Categories of occurrences that 
are analyzed include transmitted infections, malignancies, 
donor reactions, clinical complications, and process-associated 
incidents.
Currently, each database entry is given a title and a unique 
numeric identifier. Through the case analysis, the entry is 
assigned an adverse occurrence type; an MPHO type; the 
time to detection; alerting signs, symptoms, and evidence 
of occurrence; the estimated frequency; demonstration of 
imputability and imputability grade; keywords; copy of the 
reference; and any expert comments about the reference or 
occurrence. To facilitate a structured database search, all cases 
have been classified according to a taxonomy of two main 
Table 1. Hemolytic transfusion reaction definitions developed by the Haemovigilance Working Party of the International Society of Blood 
Transfusion2
Adverse transfusion reaction Definition
Hemolytic transfusion 
reactions (general)
A hemolytic transfusion reaction is one in which symptoms and clinical or laboratory signs of increased red cell 
destruction are produced by transfusion. Hemolysis can occur intravascularly or extravascularly and can be immediate 
(acute) or delayed.
Acute hemolytic transfusion 
reaction (AHTR)
AHTR has its onset within 24 hours of a transfusion. Clinical or laboratory features of hemolysis are present.
Not all clinical or laboratory features are present in cases of AHTR. Blood group serology usually shows abnormal results 
but absence of immunological findings does not exclude AHTR. AHTR may also be due to erythrocyte auto-antibodies 
in the recipient or to non-immunological factors like mechanical factors inducing hemolysis (malfunction of a pump, of a 
blood warmer, use of hypotonic solutions, etc.).
Delayed hemolytic 
transfusion reaction (DHTR)
DHTR usually manifests between 24 hours and 28 days after a transfusion and clinical or laboratory features of hemolysis 
are present. Signs and symptoms are similar to AHTR but are usually less severe. DHTR may sometimes manifest as an 
inadequate rise of post-transfusion hemoglobin level or unexplained fall in hemoglobin after a transfusion. Blood group 
serology usually shows abnormal results.
Delayed serologic reaction 
(DSTR)
There is a DSTR when, after a transfusion, there is demonstration of clinically significant antibodies against red blood 
cells which were previously absent (as far as is known) and when there are no clinical or laboratory features of hemolysis. 
This term is synonymous with alloimmunization.
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Table 2. Non-hemolytic transfusion reaction definitions developed by the Haemovigilance Working Party of the International Society of 
Blood Transfusion2
Adverse transfusion reaction Definition
Febrile non hemolytic 
transfusion reaction 
(FNHTR)
There is a FNHTR in the presence of one or more of the following: fever (≥38°C oral or equivalent and a change of ≥1°C 
from pretransfusion value), chills/rigors. These may be accompanied by headache and nausea. Symptoms occurring 
during or within four hours following transfusion without any other cause such as hemolytic transfusion reaction, bacterial 
contamination or underlying condition. FNHTR could be present in absence of fever (if chills or rigors without fever).
Allergic reaction An allergic reaction may present only with mucocutaneous signs and symptoms: morbilliform rash with pruritus; urticaria 
(hives); localized angioedema; edema of lips, tongue, and uvula; periorbital pruritus, erythema and edema; conjunctival 
edema. Occurring during or within 4 hours of transfusion. In this form it usually presents no immediate risk to life of patient 
and responds quickly to symptomatic treatment like antihistamine or steroid medications. This type of allergic reaction 
is called ‘minor allergic reaction’ in many hemovigilance systems. For the purpose of classification this type of allergic 
reaction would be graded as 1, i.e. non-severe.
An allergic reaction can also involve respiratory and/or cardiovascular systems and present like an anaphylactic reaction. 
There is anaphylaxis when, in addition to mucocutaneous systems there is airway compromise or severe hypotension 
requiring vasopressor treatment (or associated symptoms like hypotonia, syncope). The respiratory signs and symptoms 
may be laryngeal (tightness in the throat, dysphagia, dysphonia, hoarseness, stridor) or pulmonary (dyspnea, cough, 
wheezing/bronchospasm, hypoxemia). Such a reaction usually occurs during or very shortly after transfusion. 
For the purpose of classification this type of allergic reaction would be graded as 2 (severe), 3 (life-threatening), or 4 
(death) depending on the course and outcome of the reaction.
An allergic reaction classically results from the interaction of an allergen and preformed antibodies. A rise of mast cell 
tryptase can support the diagnosis of an allergic reaction. IgA deficiency and/or anti-IgA in the recipient has been 




TA-GVHD is a clinical syndrome characterized by symptoms of fever, rash, liver dysfunction, diarrhea, pancytopenia, and 
findings of characteristic histological appearances on biopsy occurring 1–6 weeks following transfusion with no other 
apparent cause. The diagnosis of TA-GVHD is further supported by the presence of chimerism.
Post-transfusion purpura 
(PTP)
PTP is characterized by thrombocytopenia arising 5–12 days following transfusion of cellular blood components with 
findings of antibodies in the patient directed against the human platelet antigen (HPA) system.
Transfusion-related acute 
lung injury (TRALI)
In patients with no evidence of acute lung injury (ALI) prior to transfusion, TRALI is diagnosed if a new ALI is present (all 
five criteria should be met): 
1) Acute onset 
2) Hypoxemia of PaO2/FiO2 <300 mmHg, or oxygen saturation of <90% on room air, or other clinical evidence
3) Bilateral infiltrates on frontal chest radiograph
4) No evidence of left atrial hypertension (i.e., circulatory overload) 
5) No temporal relationship to an alternative risk factor for ALI, during or within 6 hours of completion of transfusion
Alternate risk factors for ALI include: direct lung injury (aspiration, pneumonia, toxic inhalation, lung contusion, near 
drowning) or indirect lung injury (severe sepsis, shock, multiple trauma, burn injury, acute pancreatitis, cardiopulmonary 
bypass, drug overdose).
Note: It has been suggested by the Toronto TRALI Consensus Panel to add a category of possible TRALI that would have 
the same definition as TRALI except for the presence of a temporal relationship to an alternative risk factor for ALI (as 
described earlier). In such a circumstance, TRALI should be indicated with a possible imputability to transfusion.
TRALI is therefore a clinical syndrome and neither presence of HLA or HNA antibodies in donor(s) nor confirmation of 




TACO is characterized by any 4 of the following occurring within 6 hours of completion of transfusion: 
1) Acute respiratory distress
2) Tachycardia
3) Increased blood pressure
4) Acute or worsening pulmonary edema on frontal chest radiograph
5) Evidence of positive fluid balance. 
An elevated brain natriuretic peptide (BNP) is supportive of TACO.
Transfusion associated 
dyspnea (TAD)
TAD is characterized by respiratory distress within 24 hours of transfusion that does not meet the criteria of TRALI, 
TACO, or allergic reaction. Respiratory distress should be the most prominent clinical feature and should not be explained 
by the patient’s underlying condition or any other known cause.
Hypotensive transfusion 
reaction
This reaction is characterized by hypotension defined as a drop in systolic blood pressure of ≥ 30 mm Hg occurring 
during or within one hour of completing transfusion and a systolic blood pressure ≤ 80 mm Hg.
Haemosiderosis Transfusion-associated haemosiderosis is defined as a blood ferritin level of ≥ 1000 micrograms/L, with or without organ 
dysfunction in the setting of repeated RBC transfusions.
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Table 2. Non-hemolytic transfusion reaction definitions developed by the Haemovigilance Working Party of the International Society of 
Blood Transfusion2 (continued)
Adverse transfusion reaction Definition
Hyperkalemia Any abnormally high potassium level (> 5 mmol/L or ≥1.5 mmol/L net increase) within an hour of transfusion can be 
classified as a transfusion- associated hyperkalemia.
Unclassifiable complication 
of transfusion (UCT)
Occurrence of an adverse effect or reaction temporally related to transfusion, which cannot be classified according to an 
already defined reaction type and with no risk factor other than transfusion and no other explaining cause.
*The definition of TACO is currently undergoing revision by the working party.
HLA = human leukocyte antigen; HNA = human neutrophil antigen; RBC = red blood cell.
Table 3. Imputability criteria developed by the Haemovigilance Working Party of the International Society of Blood Transfusion2
Imputability category* Definition
Definite (certain) There is conclusive evidence beyond reasonable doubt that the adverse event can be attributed to the transfusion.
Probable (likely) The evidence is clearly in favor of attributing the adverse event to the transfusion.
Possible The evidence is indeterminate for attributing the adverse event to the transfusion or an alternate cause.
Unlikely (doubtful) The evidence is clearly in favor of attributing the adverse event to causes other than the transfusion.
Excluded There is conclusive evidence beyond reasonable doubt that the adverse event can be attributed to causes other than the 
transfusion.
*Only definite, probable, and possible cases should be used for international comparisons.
Fig. 1 Adverse occurrence type taxonomy (extract). AHTR = acute hemolytic transfusion reaction; DHTR = delayed hemolytic transfusion 
reaction; DSTR = delayed serologic transfusion reaction; Detr. Imm. = detrimental immunization; GvHD = graft-versus-host disease; PTP = 
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groups—adverse occurrence type (harm to a recipient, harm to 
a donor, harm to a fetus or offspring, risk of harm) and MPHO 
type (organs, blood, cells, tissues, etc.). Figure 1 provides 
an extract of the taxonomy for adverse occurrence type. For 
example, immunological complications are further categorized 
into AHTRs, allergic reactions, DHTRs, DSTRs, detrimental 
immunization, graft-versus-host disease, post-transfusion 
purpura, rejection, and transfusion-related acute lung injury 
(TRALI). Figure 2 provides the taxonomy applied for MPHO 
type. This predefined classification enables searching by 
adverse occurrence type, by MPHO type, or both, as well as by 
using free text or key words.
Of the current searchable entries in the Notify Library, 
68 percent are classified as harm to recipient, 18 percent 
are classified as harm to donor, 13 percent are classified as 
risk of harm, and the remaining 1 percent are classified as 
harm to fetus or offspring. Not surprisingly, among entries 
relating to recipient harm, 52 percent are subsequently 
categorized as relating to infection and 17 percent as relating 
to immunological complications. Of the 331 reports of adverse 
occurrences associated with the MPHO of blood, 57 percent 
are related to transfusion of red blood cells, 21 percent to 
platelets, 11 percent to plasma, 7 percent to whole blood, and 
1 percent to granulocytes; the remaining are not specified. Of 
the 89 percent of blood reports of the occurrence type harm to 
recipient, 49 percent of reports are immunological in nature 
(Fig. 3), including DHTRs, AHTRs, DSTRs, TRALI, and 
allergic reactions.
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Current Notify Library Activities
Competent authorities for blood, tissues, and cells in the 
28 countries of the EU have been approached through the 
Vigilance and Inspection for the Safety of Transfusion, Assisted 
Reproduction and Transplantation (VISTART) Joint Action 
supported by the European Commission and coordinated by 
CNT (since VISTART includes a specific Work Package on 
Vigilance Communication dedicated to the Notify Library). 
Moreover, a directory of vigilance is being created through the 
WHO regional offices to associate all competent authorities for 
MPHO at a global level to facilitate member states’ access and 
contribution to the Notify project, building a global network of 
experts who are learning from each other.
Since the beginning of the project, annual consultations 
have been organized and, thanks to the collaboration of all 
editorial group members, the database is regularly updated 
and the Web site continues to improve. Further tools to support 
vigilance have been developed over the years, including a 
comprehensive vigilance document available for download 
through the related section (Notify Booklet, currently in 
revision for the inclusion of hemovigilance data) and the ability 
to access a panel of experts providing support and advice on 
request via the Notify Web site.
Invitation to Join and Contribute
The Notify Library and the team of professionals 
associated with its creation and maintenance are a global 
resource in the area of biovigilance that encourages broad 
global participation in the project. Access is open to the public. 
Individual users are encouraged to search and review the 
contents of the Library. Clinical and laboratory practitioners 
and students are invited to identify information that might be 
still missing, to refer new cases, propose new entries, involve 
students and clinicians from domains outside transfusion 
and transplantation, recommend references, and even join 
an editorial group to review new cases. All organizations, 
authorities, or professional societies that work on the safety 
and quality of MPHO are invited to support and contribute to 
this didactic initiative.
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Fig. 3 Immunologic complications described in the Notify Library. 
TRALI = transfusion-related acute lung injury; DSTR = delayed 
serologic transfusion reaction; AHTR = acute hemolytic transfusion 
reaction; DHTR = delayed hemolytic transfusion reaction.
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